Daniel Khera-Mcrackan, MD
Urology · Raleigh, NCNPI 1689896219
Payments from drug & device makers
Across 374 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Johnson & Johnson$1K
- Dendreon Pharmaceuticals LLC$961
- AbbVie$625
- Merck$564
- Myriad Genetic Laboratories, Inc.$359
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,73994%
- Education$4036%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 65 | $1,245 |
| Johnson & Johnson | 50 | $1,020 |
| Dendreon Pharmaceuticals LLC | 44 | $961 |
| AbbVie(2 entities) | 39 | $625 |
| Merck | 31 | $564 |
| Myriad Genetic Laboratories, Inc. | 16 | $359 |
| Blue Earth Diagnostics | 15 | $299 |
| Sumitomo Pharma America, Inc. | 14 | $276 |
| Urovant Sciences Inc | 14 | $225 |
| Pfizer | 10 | $192 |
| Antares Pharma, Inc. | 9 | $145 |
| Urogen Pharma, Inc. | 6 | $113 |
| Bayer | 5 | $91 |
| Acerus Pharmaceuticals Corporation | 5 | $81 |
| Tolmar, Inc. | 3 | $77 |
| Procept Biorobotics Corporation | 1 | $77 |
| AstraZeneca | 4 | $76 |
| Myovant Sciences Inc. | 4 | $75 |
| Olympus America Inc. | 4 | $74 |
| Tolmar Pharmaceuticals, Inc. | 3 | $62 |
| Clarus Therapeutics Inc. | 5 | $61 |
| Boston Scientific | 4 | $61 |
| Endo Pharmaceuticals Inc. | 4 | $56 |
| Amgen | 3 | $52 |
| Progenics Pharmaceuticals, Inc. | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 3 | $42 |
| Endo USA, Inc. | 2 | $39 |
| Accord Healthcare, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Halozyme Inc | 1 | $18 |
| Baudax Bio Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $17 |
| Telix Pharmaceuticals | 1 | $16 |
| Coloplast | 1 | $14 |
| KARL Storz Endoscopy-america | 1 | $13 |
| Ambu Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,141 in reported general payments places this provider in the 70th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 227 | $2,759,028 |
| NubeqaDarolutamide | 43 | $561,490 |
| ErleadaApalutamide | 30 | $419,288 |
| OrgovyxRelugolix | 47 | $129,074 |
| GemtesaVibegron | 155 | $115,687 |
| MyrbetriqMirabegron | 73 | $59,730 |
| Abiraterone Acetate | 85 | $56,249 |
| Tamsulosin Hcl | 588 | $8,858 |
| Potassium Citrate ErPotassium Citrate | 95 | $7,971 |
| ElmironPentosan Polysulfate Sodium | 11 | $6,991 |
| Testosterone | 21 | $6,007 |
| Dutasteride | 191 | $5,619 |
| Finasteride | 294 | $4,901 |
| Trimethoprim | 57 | $4,720 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 184 | $4,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,245 | $2,818,758300 claims |
| BayerNubeqa | $91 | $561,49043 claims |
| Johnson & JohnsonErleada | $1,020 | $419,28830 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $276 | $244,761202 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 434 urology providers in North Carolina.
Other urology in Raleigh
- John KasparRaleigh$1.1M
- Mark JalkutRaleigh$516K
- Aaron LentzRaleigh$371K
- Daniel GeorgeDurham$17.6M
- Robert LippittSmithfield$11.4M
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- John WrennGreensboro$2.9M
- Michael KennellyCharlotte$1.4M
- Scott MacdiarmidGreensboro$882K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.